Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLH | Q9Y253 | 8/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.72 |
| ▸ | MEN1 | O00255 | 4/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.72 |
| ▸ | POLB | P06746 | 4/20 | 0.72 |
| ▸ | RECQL | P46063 | 4/20 | 0.72 |
| ▸ | GAA | P10253 | 3/20 | 0.72 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.72 |
| ▸ | APEX1 | P27695 | 3/20 | 0.72 |
| ▸ | MMP1 | P03956 | 2/20 | 0.72 |
| ▸ | MAPT | P10636 | 2/20 | 0.72 |
| ▸ | BLM | P54132 | 2/20 | 0.72 |
| ▸ | HTT | P42858 | 1/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.65 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.65 |
| ▸ | USP2 | O75604 | 2/20 | 0.65 |
| ▸ | TP53 | P04637 | 2/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29897597 | 1.00 | POLH (0.72) | POLHKDM4EMEN1KMT2APOLB | |
| SCHEMBL10861623 | 0.92 | POLH (0.78) | POLHKDM4EMEN1KMT2APOLB | |
| SCHEMBL8015255 | 0.91 | TUBB4A (0.67) | POLHKDM4EMEN1KMT2APOLB | |
| SCHEMBL11208005 | 0.91 | F10 (0.64) | POLHKDM4EMEN1KMT2APOLB | |
| Potassium Ion SCHEMBL4649852 | 0.89 | POLH (0.71) | POLHKDM4EMEN1KMT2APOLB | |
| SCHEMBL3637097 | 0.89 | POLH (0.71) | POLHKDM4EMEN1KMT2APOLB | |
| SCHEMBL3735018 | 0.88 | MEN1 (0.71) | POLHKDM4EMEN1KMT2APOLB | |
| SCHEMBL3727374 | 0.88 | TUBB4A (0.80) | POLHKDM4EMEN1KMT2APOLB | |
| SCHEMBL14786208 | 0.86 | POLH (0.81) | POLHKDM4EMEN1KMT2APOLB | |
| SCHEMBL3642770 | 0.85 | TUBB4A (0.69) | POLHKDM4EMEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3655015-B1 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING RADIATION-INDUCED BYSTANDER EFFECTS CAUSED BY RADIATION OR RADIOTHERAPY | UNIV COLORADO REGENTS (US) | 2024-02-21 | — | — | EP | claimed |
| US-20230233517-A1 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING RADIATION-INDUCED BYSTANDER EFFECTS CAUSED BY RADIATION OR RADIOTHERAPY | TSINGHUA UNIVERSITY (CN) | 2023-07-27 | — | — | US | claimed |
| EP-3655015-A2 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING RADIATION-INDUCED BYSTANDER EFFECTS CAUSED BY RADIATION OR RADIOTHERAPY | The Regents of the University of Colorado (US) | 2020-05-27 | — | — | EP | claimed |
| US-20200155502-A1 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING RADIATION-INDUCED BYSTANDER EFFECTS CAUSED BY RADIATION OR RADIOTHERAPY | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2020-05-21 | — | — | US | claimed |
| WO-2019018451-A2 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING RADIATION-INDUCED BYSTANDER EFFECTS CAUSED BY RADIATION OR RADIOTHERAPY | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2019-01-24 | — | — | WO | claimed |
| US-20100279961-A1 | PHARMACEUTICAL COMPOSITION HAVING A TRIHYDROXY-CHROMENONE DERIVATIVE | ANALYTICON DISCOVERY GMBH (DE) | 2010-11-04 | — | — | US | claimed |
| EP-2164477-A1 | PHARMACEUTICAL COMPOSITION HAVING A TRIHYDROXY-CHROMENONE DERIVATIVE | Analyticon Discovery GmbH (DE) | 2010-03-24 | — | — | EP | claimed |
| WO-2008154900-A1 | PHARMACEUTICAL COMPOSITION HAVING A TRIHYDROXY-CHROMENONE DERIVATIVE | ANALYTICON DISCOVERY GMBH (DE) | 2008-12-24 | — | — | WO | claimed |
| US-20040162247-A1 | Therapeutic agent or osteoporosis comprising an active ingredient of quercetin derivatives | KIM CHUNG-SOOK (KR) | 2004-08-19 | — | — | US | claimed |
| EP-1309326-A1 | A THERAPEUTIC AGENT OF OSTEOPOROSIS COMPRISING AN ACTIVE INGREDIENT OF QUERCETIN DERIVATIVES | Korea Institute of Oriental Medicine (KR) | 2003-05-14 | — | — | EP | claimed |
| US-20020165169-A1 | Therapeutic agent of osteoporosis comprising an active ingredient of quercetin derivatives | KOREA INSTITUTE OF ORIENTAL MEDICINE (KR) | 2002-11-07 | — | — | US | claimed |
| WO-2002017909-A1 | A THERAPEUTIC AGENT OF OSTEOPOROSIS COMPRISING AN ACTIVE INGREDIENT OF QUERCETIN DERIVATIVES | KOREA INSTITUTE OF ORIENTAL MEDICINE (KR) | 2002-03-07 | — | — | WO | claimed |
| JP-6017051-A | — | — | None | — | — | JP | disclosed |
| US-12447142-B2 | Compositions and methods for preventing and treating radiation-induced bystander effects caused by radiation or radiotherapy | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2025-10-21 | — | — | US | disclosed |
| CN-120082459-A | Lactobacillus plantarum and application thereof in fermenting pagodatree flower to relieve hyperuricemia | 华南理工大学 | 2025-06-03 | — | — | CN | disclosed |
| CN-110831589-B | Medical compounds | 维拉萨卢斯里切尔卡有限公司 | 2025-01-03 | — | — | CN | disclosed |
| EP-0817862-A1 | ONE-POT ENZYMATIC SULFATION PROCESS USING 3'-PHOSPHOADENOSINE-5'-PHOSPHOSULFATE AND RECYCLED PHOSPHORYLATED ADENOSINE INTERMEDIATES | THE SCRIPPS RESEARCH INSTITUTE (US) | 1998-01-14 | — | — | EP | disclosed |
| WO-1996029424-A9 | ONE-POT ENZYMATIC SULFATION PROCESS USING 3'-PHOSPHOADENOSINE-5'-PHOSPHOSULFATE AND RECYCLED PHOSPHORYLATED ADENOSINE INTERMEDIATES | — | 1996-11-21 | — | — | WO | disclosed |
| WO-1996029424-A1 | ONE-POT ENZYMATIC SULFATION PROCESS USING 3'-PHOSPHOADENOSINE-5'-PHOSPHOSULFATE AND RECYCLED PHOSPHORYLATED ADENOSINE INTERMEDIATES | THE SCRIPPS RESEARCH INSTITUTE (US) | 1996-09-26 | — | — | WO | disclosed |
| JP-H0617051-A | ANTIOXIDANT | MARUZEN PHARMACEUT CO LTD | 1994-01-25 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12447142-B2 | Compositions and methods for preventing and treating radiation-induced bystander effects caused by radiation or radiotherapy | CTSE, CTSB, ATG4B | POLH 2342/4885KDM4E 157/4885MEN1 4235/4885 |
| US-20100279961-A1 | PHARMACEUTICAL COMPOSITION HAVING A TRIHYDROXY-CHROMENONE DERIVATIVE | UGT2B17, UGT1A3, UGT1A4 | POLH 3433/4885KDM4E 2162/4885MEN1 2912/4885 |
| US-20230233517-A1 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING RADIATION-INDUCED BYSTANDER EFFECTS CAUSED BY RADIATION OR RADIOTHERAPY | CTSE, CTSB, ATG4B | POLH 2342/4885KDM4E 157/4885MEN1 4235/4885 |
| US-20040162247-A1 | Therapeutic agent or osteoporosis comprising an active ingredient of quercetin derivatives | NFATC1, MKI67, SOST | POLH 3604/4885KDM4E 952/4885MEN1 2365/4885 |
| US-20020165169-A1 | Therapeutic agent of osteoporosis comprising an active ingredient of quercetin derivatives | NFATC1, MKI67, SOST | POLH 3627/4885KDM4E 893/4885MEN1 2560/4885 |
| US-20200155502-A1 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING RADIATION-INDUCED BYSTANDER EFFECTS CAUSED BY RADIATION OR RADIOTHERAPY | CTSE, CTSB, ATG4B | POLH 2342/4885KDM4E 157/4885MEN1 4235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.